Blab Business
Syndax Pharmaceuticals Holds 2026 Annual Shareholder Meeting Amid Strong Oncology Pipeline and Recent Financial Growth
On June 10, 2026, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) convened its annual meeting of stockholders through a recorded virtual session. Chairman Dennis Podlesak opened the proceedings, introduced the board of directors and executive team, and outlined the agenda, which covered formal business items, proxy voting, and a question‑and‑answer segment.
Podlesak greeted participants and listed the board members present—Michael Metzger, CEO; Marty Huber; Jennifer Jarrett; Keith Katkin; Pierre Legault; and Aleksandra Rizo. He also named company officers, including Luke Albrecht, General Counsel, and Keith Goldan, Chief Financial Officer, and noted that Deloitte & Touche auditors Jeff Kirkland and Tinik Caporo would be on hand to answer questions.
The meeting’s purpose was to conduct the formal business of the annual meeting as set out in the proxy statement and to give shareholders a forum for questions. The session was recorded, and the transcript of the Chairman’s remarks is publicly available.
Syndax is a commercial‑stage biopharmaceutical company that focuses on precision oncology. Its flagship product, Revuforj (revumenib), received U.S. FDA approval on December 26, 2024 for treating acute myeloid leukemia (AML) patients with KMT2A rearrangements. The approval followed a series of clinical studies that demonstrated the drug’s ability to disrupt the menin‑KMT2A interaction, a key driver of leukemogenesis.
Beyond Revuforj, Syndax’s pipeline includes entinostat (SNDX‑275), a histone deacetylase inhibitor acquired by the company and advanced for the treatment of resistant cancers. According to a company filing, Syndax received $26.6 million in funding to support entinostat’s development.
Financially, Syndax has posted significant revenue growth in recent quarters. The company’s Q4 2025 earnings release reported total revenue of $172 million for the year ended December 31, 2025, driven by the launch of Revuforj and the commercial launch of Niktimvo. In the first quarter of 2026, the earnings‑call transcript indicated revenue of $64.86 million and a net loss of $42.67 million, a narrowing of the loss compared with $84.85 million in Q1 2025.
The stock has reflected this commercial momentum. As of June 10, 2026, the share price was trading near $19.11, up more than 38 % over the previous 12 months. Analysts note that the price movement aligns with the company’s expanding indications for Revuforj and the progress of its pipeline assets.
Looking ahead, Syndax will hold its next earnings call on July 30, 2026, where it is expected to provide updates on ongoing clinical trials and commercial sales. Shareholders will also vote on the election of directors and any proposals outlined in the proxy statement.
The meeting concluded with the formal business of the annual meeting and an invitation for shareholders to submit questions. The event was conducted in compliance with Nasdaq’s requirements for virtual shareholder meetings.
In summary, Syndax’s 2026 annual meeting highlighted its leadership team, reaffirmed its focus on precision oncology, and underscored recent revenue growth and a narrowing loss. The company’s ongoing clinical and commercial activities, coupled with its FDA‑approved product, position it for continued scrutiny from investors and regulators in the coming months.
Podlesak greeted participants and listed the board members present—Michael Metzger, CEO; Marty Huber; Jennifer Jarrett; Keith Katkin; Pierre Legault; and Aleksandra Rizo. He also named company officers, including Luke Albrecht, General Counsel, and Keith Goldan, Chief Financial Officer, and noted that Deloitte & Touche auditors Jeff Kirkland and Tinik Caporo would be on hand to answer questions.
The meeting’s purpose was to conduct the formal business of the annual meeting as set out in the proxy statement and to give shareholders a forum for questions. The session was recorded, and the transcript of the Chairman’s remarks is publicly available.
Syndax is a commercial‑stage biopharmaceutical company that focuses on precision oncology. Its flagship product, Revuforj (revumenib), received U.S. FDA approval on December 26, 2024 for treating acute myeloid leukemia (AML) patients with KMT2A rearrangements. The approval followed a series of clinical studies that demonstrated the drug’s ability to disrupt the menin‑KMT2A interaction, a key driver of leukemogenesis.
Beyond Revuforj, Syndax’s pipeline includes entinostat (SNDX‑275), a histone deacetylase inhibitor acquired by the company and advanced for the treatment of resistant cancers. According to a company filing, Syndax received $26.6 million in funding to support entinostat’s development.
Financially, Syndax has posted significant revenue growth in recent quarters. The company’s Q4 2025 earnings release reported total revenue of $172 million for the year ended December 31, 2025, driven by the launch of Revuforj and the commercial launch of Niktimvo. In the first quarter of 2026, the earnings‑call transcript indicated revenue of $64.86 million and a net loss of $42.67 million, a narrowing of the loss compared with $84.85 million in Q1 2025.
The stock has reflected this commercial momentum. As of June 10, 2026, the share price was trading near $19.11, up more than 38 % over the previous 12 months. Analysts note that the price movement aligns with the company’s expanding indications for Revuforj and the progress of its pipeline assets.
Looking ahead, Syndax will hold its next earnings call on July 30, 2026, where it is expected to provide updates on ongoing clinical trials and commercial sales. Shareholders will also vote on the election of directors and any proposals outlined in the proxy statement.
The meeting concluded with the formal business of the annual meeting and an invitation for shareholders to submit questions. The event was conducted in compliance with Nasdaq’s requirements for virtual shareholder meetings.
In summary, Syndax’s 2026 annual meeting highlighted its leadership team, reaffirmed its focus on precision oncology, and underscored recent revenue growth and a narrowing loss. The company’s ongoing clinical and commercial activities, coupled with its FDA‑approved product, position it for continued scrutiny from investors and regulators in the coming months.
